Analysts at leading investment research firm Zacks have recently presented their short-term rating on Gilead Sciences Inc., the famous biopharmaceutical company. Analysts gave Gilead Science Inc. the first rank.

A team of 11 analysts with Zacks gave Gilead Sciences Inc. with a rating of strong buy. The company has been rated as hold from 1 Wall Street Analysts. As per report, three analysts suggested buy for the share of the company and a sell call was given by only one analyst.

In total the 13 analysts stated that the short term target price of the company has been estimated at $123.62. The target price could deviate by a maximum of $15.01 from the forecast price. It could even hit a high of $135 and a low of $81.

Several other analysts have commented on the company rating. Deutsche Bank maintains its rating on Gilead Sciences, Inc. The global brokerage major raises the current price target from $125 per share to $135 per share.

Analysts at the Deutsche Bank have a current rating of Buy on the shares. The rating by the firm was issued on July 29, 2015. Shares of Gilead Science, Inc. rose 1.87% or 2.14 points on Monday.

After trading began at $115.73 the stock hit $117.12 as a peak level and $115.51 as the lowest level. The company’s stock ended at $116.58. The company has a market cap of $171,094 million.

It has been said that the company has disclosed insider buying and selling activities to the Securities Exchange. Carter Paul Rutherford, officer of Gilead Sciences Inc, unloaded 5,000 shares at an average price of $119.32 on August 3, 2015.